一种活体减弱的人类羊肉轮状病毒重组剂在小鼠中赋予了强大的保护性免疫力
Guiying Kou1, Yahui Cheng1, Guoxiang Zhang2
1Lanzhou Institute of Biological Products Co., Ltd., Lanzhou 730046, China; State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing 100024, China.
Vaccine
|October 29, 2025
概括
一种新的轮状病毒候选疫苗,LG9,显示了预防儿童严重胃肠炎的前景. 这种活体减弱疫苗在临床前研究中证明了安全性和有效性,为抗击轮状病毒疾病提供了潜在的新工具.
科学领域:
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
- 儿童传染病 儿童传染病
背景情况:
- 在全球范围内,A组轮状病毒 (RVA) 是严重胃肠炎和幼儿死亡的主要原因.
- 目前的轮状病毒疫苗使用减弱的人类菌株或人动物复合剂,持续需要改进的候选疫苗.
- 兰州羔羊轮状病毒 (LLR) 骨干为新型疫苗开发提供了一个潜在的平台.
研究的目的:
- 开发和表征LG9,一种新型单基组组合剂轮状病毒疫苗候选人.
- 在临床前模型中评估LG9的遗传稳定性,复制性,免疫性和保护功效.
- 评估LLR骨干在制造多价值轮状病毒疫苗方面的实用性.
主要方法:
- 通过将LLR的VP7基因 (G10P[15]) 替换为人类G9P[8] VP7抗原来对LG9菌株进行工程.
- 在MA104和Vero细胞系中评估遗传稳定性和复制动力学.
- 通过口服或腹腔内途径对小鼠进行免疫接种,然后测量抗体标位并与轮状病毒挑战.
- 评估对临床症状的保护,包括腹,发烧和减肥.
主要成果:
- 这种LG9菌株在细胞培养中表现出强大的遗传稳定性和高效的复制性,与父母LLR相美.
- 免疫接种诱导了小鼠的高中和抗体标位,在增强 (>20倍) 后观察到显著增加.
- 接种疫苗的小鼠对轮状病毒具有显著的保护,与对照组相比,症状减少,没有观察到不良影响.
结论:
- LG9 是一种安全且免疫性单重组合的轮状病毒疫苗候选剂,其临床前有效性已被证明.
- 该LLR骨干被验证为开发下一代,潜在多价值,活减弱的轮状病毒疫苗的灵活平台.
- 这些发现支持进一步开发LG9作为对儿童轮状病毒胃肠炎的潜在干预措施.
相关概念视频
Viral Recombination
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
Rabies
Rabies is a lethal zoonotic disease caused by a single-stranded, negative-sense RNA virus of the Lyssavirus genus, within the family Rhabdoviridae. Its primary mode of transmission to humans is through bites or saliva-contaminated scratches from infected mammals such as dogs, bats, raccoons, or foxes. Transmission can also occur if infectious saliva contacts abraded skin or intact mucous membranes, including the conjunctiva.Viral Entry and Early ReplicationOnce introduced at the bite or scratch...


